• Morgan Smith, Austin Ridgway, and Dolores Mullikin.
• Pediatric Residency Program, Tripler Army Medical Center, Honolulu, HI 96859, USA.
• Mil Med. 2024 May 18; 189 (5-6): e1259e1262e1259-e1262.

IntroductionTreatment of neonatal hyperbilirubinemia remains one of the most common reasons for readmission following delivery. Revised clinical practice guidelines (CPGs) for the treatment of neonatal hyperbilirubinemia were published on August 5, 2022. This report describes the preliminary outcomes following implementation of the new CPGs at Tripler Army Medical Center.Materials And MethodsA retrospective chart review was performed for the 12 months prior to implementation and the 5 months post implementation.ResultsBilirubin admissions decreased from 15.6% of total admissions during the 12 months prior to the new guidelines (69/441) to 4.1% of admissions (8/194) during the 5 months after implementation of the new guidelines (P < 0.001). This corresponds to a 74% reduction (risk ratio = 0.26, 95% confidence interval [CI] 0.13 to 0.54). The decrease in admissions was found to correlate to greater than $140,000 in annual savings.ConclusionAdhering to the revised CPGs has the potential to increase resource availability at a time when nursing shortages and financial instability are impacting health care systems nationwide. No short-term adverse events were noted; however, long-term follow up will be needed.© The Association of Military Surgeons of the United States 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

28 keywords...

hide…